Skip to main content
Oxford University Hospitals NHS Foundation Trust
Oxford Genomic Medicine Centre

This site is best viewed with a modern browser. You appear to be using an old version of Internet Explorer.


Who is eligible?

Most patients invited to take part will have been recently diagnosed with one of the cancers listed below, and will yet to have started treatment. Some patients who have had previous treatment, including chemotherapy or radiotherapy, may also be eligible.

Advice on any aspect of the cancer programme is available on request. Our Cancer Genomic Champion, Jane Niederer, Lead Research Nurse, can help with individual enquiries or arrange to speak to your team.

Oxford GMC is currently recruiting patients with the following types of cancer:

  • prostate
  • renal
  • lung
  • breast
  • colorectal
  • ovarian
  • sarcoma
  • testicular
  • endometrial
  • esophageal
  • pancreatic

and also haematological malignancies.

Adult patients with brain tumours will also be eligible for recruitment in 2018.


Our team is happy to help with recruitment, but if you prefer, you can recruit your patients yourself or through your local team.

All staff taking consent must be accredited by completing the HEE online course:

'100,000 Genomes Project: Preparing for the Consent Conversation'

Face-to-face individual or group training sessions with the local team can also be arranged on request: see 'Training and education' for more information, or contact us to discuss your requirements.


Anyone using the 100,000 Genomes Project consent form must have valid Good Clinical Practice (GCP) training.

Participants can withdraw at any time without giving a reason. Please see the Genomics England website for further details.

Any participant wishing to withdraw or change their consent options can also contact us.


Oxford NHS GMC Cancer Newsletter

The latest version of the cancer newsletter is available at the link below.

Cancer Newsletter (Autumn 2017)

If you would like to be added to the email distribution list for the newsletter, please email us.